4//SEC Filing
Grossman Adam S 4
Accession 0001140361-25-042997
CIK 0001368514other
Filed
Nov 20, 7:00 PM ET
Accepted
Nov 21, 9:00 PM ET
Size
13.7 KB
Accession
0001140361-25-042997
Insider Transaction Report
Form 4
Grossman Adam S
DirectorPresident & CEO10% Owner
Transactions
- Exercise/Conversion
Common Stock
2025-11-19$5.40/sh+15,000$81,000→ 2,034,850 total - Sale
Common Stock
2025-11-19$16.00/sh−15,000$240,000→ 2,019,850 total - Sale
Common Stock
2025-11-19$16.00/sh−6,000$96,000→ 2,013,850 total - Exercise/Conversion
Stock Option (right to buy)
2025-11-19−15,000→ 735,950 totalExercise: $5.40Exp: 2034-02-26→ Common Stock (15,000 underlying)
Holdings
- 1,143,426(indirect: See Footnote)
Common Stock
- 580,957(indirect: See Footnote)
Common Stock
Footnotes (8)
- [F1]Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.
- [F2]The price reported in Column 4 is the price at which the shares were sold.
- [F3]Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
- [F4](continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
- [F5](continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 981,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
- [F6]These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
- [F7]These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.
- [F8]The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
Documents
Issuer
ADMA BIOLOGICS, INC.
CIK 0001368514
Entity typeother
Related Parties
1- filerCIK 0001542517
Filing Metadata
- Form type
- 4
- Filed
- Nov 20, 7:00 PM ET
- Accepted
- Nov 21, 9:00 PM ET
- Size
- 13.7 KB